Clinical Trial

A Longitudinal Natural History Study of OPA1-Associated Autosomal-Dominant Optic Atrophy

Study acronym: OPA-LONG
Recruiting
View on ClinicalTrials.gov →
Summary
This prospective, monocenter, non-interventional observational study investigates the natural history as well as the clinical and genetic spectrum of OPA1-associated autosomal dominant optic atrophy. Participants will undergo standardized ophthalmic and functional assessments, including visual acuity testing, visual field testing, color vision and contrast sensitivity testing, optical coherence tomography, retinal flavoprotein fluorescence imaging, and video-oculography-based ocular motor and pupillary measurements. The study aims to characterize disease severity and progression over time and to identify structural, metabolic, and functional biomarkers that may serve as clinical endpoints for future therapeutic studies.
Trial Details
NCT Number NCT07729982
Lead Sponsor Ludwig-Maximilians - University of Munich
Conditions OPA1 Gene Mutation, Optic Atrophy, Autosomal Dominant
Enrollment 50 participants
Start Date 2026-07-16
Primary Completion 2030-10 (estimated)
Study Completion 2030-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-28